IntroductionOvarian cancer is one of the most lethal gynecological tumors with a lack of effective treatment modalities especially in advanced/recurrent disease. Nevertheless, recently, new small molecules have emerged as an effective approach for the management of ovarian cancer patients, especially in the maintenance setting.Areas coveredThis review summarizes the role of small molecules used in the management of high-grade serous ovarian cancer. The authors performed a critical review of current evidence and ongoing studies. Of note, tyrosine kinase inhibitors (TKIs) and poly(ADP-ribose) polymerase (PARP) inhibitors are the most intriguing medications in this setting.Expert opinionProtein-targeted therapies against tumor tissues have progressed significantly in the last years due to an enhanced knowledge of the biological and molecular processes of carcinogenesis. Treatment with small molecules allows the targeting of specific proteins involved in cancer biology. TKIs seem promising but further data are necessary to assess the pros and cons of adopting this treatment modality. PARP inhibitors represent the new standard of care for ovarian cancer patients harboring either a BRCA mutation or with homologous recombination deficiency (HRD). Interestingly, the accumulation of data has highlighted that PARP inhibitors provide benefits even in patients with HR proficient tumors.

Advances in small molecule maintenance therapies for high-grade serous ovarian cancer / Fischetti, Margherita; Di Donato, Violante; Palaia, Innocenza; Perniola, Giorgia; Tomao, Federica; Perrone, Chiara; Giancotti, Antonella; Di Mascio, Daniele; Monti, Marco; Muzii, Ludovico; Benedetti Panici, Pierluigi; Bogani, Giorgio. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 24:1(2023), pp. 65-72. [10.1080/14656566.2022.2154144]

Advances in small molecule maintenance therapies for high-grade serous ovarian cancer

Fischetti, Margherita;Di Donato, Violante;Palaia, Innocenza;Perniola, Giorgia;Tomao, Federica;Perrone, Chiara;Giancotti, Antonella;Di Mascio, Daniele;Monti, Marco;Muzii, Ludovico;Benedetti Panici, Pierluigi;Bogani, Giorgio
2023

Abstract

IntroductionOvarian cancer is one of the most lethal gynecological tumors with a lack of effective treatment modalities especially in advanced/recurrent disease. Nevertheless, recently, new small molecules have emerged as an effective approach for the management of ovarian cancer patients, especially in the maintenance setting.Areas coveredThis review summarizes the role of small molecules used in the management of high-grade serous ovarian cancer. The authors performed a critical review of current evidence and ongoing studies. Of note, tyrosine kinase inhibitors (TKIs) and poly(ADP-ribose) polymerase (PARP) inhibitors are the most intriguing medications in this setting.Expert opinionProtein-targeted therapies against tumor tissues have progressed significantly in the last years due to an enhanced knowledge of the biological and molecular processes of carcinogenesis. Treatment with small molecules allows the targeting of specific proteins involved in cancer biology. TKIs seem promising but further data are necessary to assess the pros and cons of adopting this treatment modality. PARP inhibitors represent the new standard of care for ovarian cancer patients harboring either a BRCA mutation or with homologous recombination deficiency (HRD). Interestingly, the accumulation of data has highlighted that PARP inhibitors provide benefits even in patients with HR proficient tumors.
2023
BRCA; PARP; Small molecule; TKI; ovarian cancer
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Advances in small molecule maintenance therapies for high-grade serous ovarian cancer / Fischetti, Margherita; Di Donato, Violante; Palaia, Innocenza; Perniola, Giorgia; Tomao, Federica; Perrone, Chiara; Giancotti, Antonella; Di Mascio, Daniele; Monti, Marco; Muzii, Ludovico; Benedetti Panici, Pierluigi; Bogani, Giorgio. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 24:1(2023), pp. 65-72. [10.1080/14656566.2022.2154144]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1668740
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact